DXCM

DexCom, Inc. NASDAQ

Healthcare ·Medical - Devices ·US · dexcom.com

$60.04

Mkt Cap $23.2B

52w Low $54.11 16.5% of range 52w High $89.98

50d MA $65.85 200d MA $69.49

P/E (TTM) 28.7x

EV/EBITDA 22.7x

P/B 8.7x

Debt/Equity 0.5x

ROE 30.5%

P/FCF 24.0x

RSI (14) —

ATR (14) —

Beta 1.56

50d MA $65.85

200d MA $69.49

Avg Volume 4.5M

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API,…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 30, 2026	AMC	0.47	0.56	+19.1%	59.55	+2.4%	+3.0%	+0.8%	+1.1%	—	—	—
Feb 12, 2026	AMC	0.65	0.68	+4.6%	65.08	-1.0%	+7.6%	+8.2%	+11.9%	+11.0%	+12.3%	—
Oct 30, 2025	AMC	0.58	0.61	+5.9%	68.20	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%	—
Jul 30, 2025	AMC	0.44	0.48	+8.2%	89.06	-3.8%	-9.3%	-11.0%	-14.4%	-15.3%	-14.2%	—
May 1, 2025	AMC	0.33	0.32	-2.2%	70.26	+7.1%	+16.2%	+14.2%	+16.0%	+18.6%	+21.5%	—
Feb 13, 2025	AMC	0.48	0.45	-6.1%	84.09	+2.3%	+5.9%	+7.7%	+6.6%	+6.2%	+5.6%	—
Oct 24, 2024	AMC	0.44	0.45	+2.3%	74.85	-1.9%	-1.9%	-3.7%	-3.5%	-4.1%	-5.8%	—
Jul 25, 2024	AMC	0.39	0.43	+10.3%	107.85	-38.8%	-40.7%	-37.4%	-35.4%	-37.1%	-34.8%	—
Apr 25, 2024	AMC	0.27	0.32	+18.5%	138.01	-4.0%	-9.9%	-8.8%	-7.7%	-8.8%	-8.2%	—
Feb 8, 2024	AMC	0.43	0.50	+16.3%	127.05	-3.2%	-5.2%	-6.8%	-7.9%	-8.1%	-7.4%	—
Oct 26, 2023	AMC	0.34	0.50	+47.1%	81.09	+14.4%	+10.1%	+4.7%	+9.5%	+16.1%	+15.5%	—
Jul 27, 2023	AMC	0.23	0.34	+47.8%	129.36	+3.9%	+2.3%	-3.7%	-5.7%	-4.3%	-5.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Canaccord Genuity	Maintains	Buy → Buy	—	$59.55	$60.99	+2.4%	+3.0%	—	—	—	—
May 1	TD Cowen	Maintains	Buy → Buy	—	$59.55	$60.99	+2.4%	+3.0%	—	—	—	—
May 1	Barclays	Maintains	Underweight → Underweight	—	$59.55	$60.99	+2.4%	+3.0%	—	—	—	—
Mar 11	Citigroup	Maintains	Buy → Buy	—	$67.79	$67.11	-1.0%	-2.2%	-3.7%	-5.2%	-2.1%	-0.7%
Mar 9	BTIG	Maintains	Buy → Buy	—	$68.10	$67.02	-1.6%	+0.9%	-0.5%	-2.6%	-4.2%	-5.7%
Feb 25	BTIG	Maintains	Buy → Buy	—	$73.09	$73.42	+0.5%	+0.1%	+1.8%	+0.5%	+0.9%	-0.0%
Feb 17	Truist	Maintains	Buy → Buy	—	$70.02	$70.25	+0.3%	+0.6%	+4.0%	+3.2%	+4.4%	+4.6%
Feb 13	BTIG	Maintains	Buy → Buy	—	$65.08	$64.44	-1.0%	+7.6%	+8.2%	+11.9%	+11.0%	+12.3%
Feb 13	Mizuho	Maintains	Outperform → Outperform	—	$65.08	$64.44	-1.0%	+7.6%	+8.2%	+11.9%	+11.0%	+12.3%
Feb 13	Wells Fargo	Maintains	Overweight → Overweight	—	$65.08	$64.44	-1.0%	+7.6%	+8.2%	+11.9%	+11.0%	+12.3%
Feb 13	Barclays	Maintains	Underweight → Underweight	—	$65.08	$64.44	-1.0%	+7.6%	+8.2%	+11.9%	+11.0%	+12.3%
Feb 13	Canaccord Genuity	Maintains	Buy → Buy	—	$65.08	$64.44	-1.0%	+7.6%	+8.2%	+11.9%	+11.0%	+12.3%
Jan 12	Barclays	Downgrade	Equal Weight → Underweight	—	$67.40	$66.74	-1.0%	+5.3%	+4.2%	+3.4%	+2.7%	+3.2%
Jan 9	Bernstein	Maintains	Outperform → Outperform	—	$68.43	$68.61	+0.3%	-1.5%	+3.7%	+2.7%	+1.9%	+1.2%
Dec 17	Mizuho	Maintains	Outperform → Outperform	—	$66.37	$66.18	-0.3%	-0.9%	-0.7%	-0.5%	+1.6%	+0.7%
Dec 11	Citigroup	Maintains	Buy → Buy	—	$67.56	$67.98	+0.6%	+2.0%	-0.9%	-2.7%	-1.8%	-2.7%
Dec 2	Morgan Stanley	Upgrade	Equal Weight → Overweight	—	$63.52	$65.09	+2.5%	+1.5%	+2.1%	+2.7%	+3.1%	+3.3%
Nov 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$55.00	$55.16	+0.3%	-0.3%	+5.7%	+8.4%	+8.6%	+5.6%
Nov 7	Argus	Maintains	Buy → Buy	—	$58.02	$58.02	+0.0%	-5.2%	-5.5%	+0.2%	+2.7%	+2.9%
Nov 3	UBS	Maintains	Buy → Buy	—	$58.22	$58.55	+0.6%	+3.8%	+5.1%	+1.8%	-0.3%	-5.5%
Nov 3	Truist	Maintains	Buy → Buy	—	$58.22	$58.55	+0.6%	+3.8%	+5.1%	+1.8%	-0.3%	-5.5%
Nov 3	Barclays	Maintains	Equal Weight → Equal Weight	—	$58.22	$58.55	+0.6%	+3.8%	+5.1%	+1.8%	-0.3%	-5.5%
Oct 31	Wells Fargo	Maintains	Overweight → Overweight	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	RBC Capital	Maintains	Outperform → Outperform	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	TD Cowen	Maintains	Buy → Buy	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	Piper Sandler	Maintains	Overweight → Overweight	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	Canaccord Genuity	Maintains	Buy → Buy	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	Citigroup	Maintains	Buy → Buy	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	JP Morgan	Maintains	Neutral → Neutral	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 31	BTIG	Maintains	Buy → Buy	—	$68.20	$59.19	-13.2%	-14.6%	-11.4%	-10.3%	-13.1%	-14.9%
Oct 15	Truist	Maintains	Buy → Buy	—	$66.21	$66.35	+0.2%	-1.2%	+0.2%	+0.6%	+3.4%	+5.3%
Oct 7	Citigroup	Maintains	Buy → Buy	—	$66.36	$66.77	+0.6%	-0.5%	+2.1%	+2.6%	-1.9%	-1.7%
Oct 1	Goldman Sachs	Maintains	Buy → Buy	—	$67.29	$67.21	-0.1%	-1.8%	-1.3%	-0.4%	-1.4%	-1.9%
Sep 29	Canaccord Genuity	Maintains	Buy → Buy	—	$67.10	$67.34	+0.4%	-1.0%	+0.3%	-1.5%	-1.0%	-0.1%
Sep 26	Baird	Maintains	Outperform → Outperform	—	$68.30	$68.05	-0.4%	-1.8%	-2.7%	-1.5%	-3.3%	-2.7%
Aug 1	Canaccord Genuity	Maintains	Buy → Buy	—	$80.77	$80.57	-0.2%	-1.8%	-5.6%	-6.6%	-5.4%	-5.4%
Jul 31	Raymond James	Maintains	Strong Buy → Strong Buy	—	$89.06	$85.70	-3.8%	-9.3%	-11.0%	-14.4%	-15.3%	-14.2%
Jul 31	Piper Sandler	Maintains	Overweight → Overweight	—	$89.06	$85.70	-3.8%	-9.3%	-11.0%	-14.4%	-15.3%	-14.2%
Jul 31	UBS	Maintains	Buy → Buy	—	$89.06	$85.70	-3.8%	-9.3%	-11.0%	-14.4%	-15.3%	-14.2%
Jul 31	Oppenheimer	Maintains	Outperform → Outperform	—	$89.06	$85.70	-3.8%	-9.3%	-11.0%	-14.4%	-15.3%	-14.2%
Jul 30	Barclays	Maintains	Equal Weight → Equal Weight	—	$89.35	$89.35	+0.0%	-0.3%	-9.6%	-11.3%	-14.7%	-15.5%
Jul 16	Mizuho	Maintains	Outperform → Outperform	—	$84.78	$85.49	+0.8%	-0.8%	-0.8%	-1.0%	-0.9%	+0.4%
Jul 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$85.33	$86.03	+0.8%	-0.6%	-1.4%	-1.4%	-1.7%	-1.5%
May 22	Citigroup	Maintains	Buy → Buy	—	$84.89	$84.90	+0.0%	-0.1%	-0.4%	+0.5%	+2.5%	-0.0%
May 5	Barclays	Maintains	Equal Weight → Equal Weight	—	$81.62	$81.65	+0.0%	-1.7%	-0.1%	+2.1%	+4.6%	+3.7%
May 2	Canaccord Genuity	Maintains	Buy → Buy	—	$70.26	$75.26	+7.1%	+16.2%	+14.2%	+16.0%	+18.6%	+21.5%
May 2	Piper Sandler	Maintains	Overweight → Overweight	—	$70.26	$75.26	+7.1%	+16.2%	+14.2%	+16.0%	+18.6%	+21.5%
May 2	Baird	Maintains	Outperform → Outperform	—	$70.26	$75.26	+7.1%	+16.2%	+14.2%	+16.0%	+18.6%	+21.5%
Mar 4	Citigroup	Maintains	Buy → Buy	—	$85.99	$85.76	-0.3%	-4.2%	-4.7%	-7.5%	-9.5%	-17.8%
Feb 14	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$84.09	$86.03	+2.3%	+5.9%	+7.7%	+6.6%	+6.2%	+5.6%

Recent Filings

8-K · 5.02 !!! Very High

DexCom, Inc. -- 8-K 5.02: Executive Change

DexCom appoints Sayer as Executive Chairman starting January 1, 2026, signaling potential strategic shifts in leadership and company direction for investors to monitor.

Mar 2

8-K · 5.02 !!! Very High

DexCom, Inc. -- 8-K 5.02: Executive Change

DexCom appointed Albert F and Mr. Osterloh as directors, expanding board oversight of the continuous glucose monitoring company's operations and strategic direction.

Feb 26

8-K

DexCom, Inc. -- 8-K Filing

DexCom reported strong fourth-quarter 2025 revenue growth of 13% year-over-year to $1.260 billion, demonstrating continued market expansion for its continuous glucose monitoring devices despite competitive pressures.

Feb 12

Data updated apr 25, 2026 6:07am · Source: massive.com